Search clinical trials for: NVX-508

Total 3863 results

Amma Owusu-Ansah, MD
NuvOx LLC; Noguchi Memorial Institute for Medical Research

Withdrawn

A Phase Ib Study of NVX-508 in Sickle Cell Disease

Sickle Cell Disease
NuvOx LLC
The Alfred

Completed

The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma (GBM)

Glioblastoma Multiforme

Australia
Resverlogix Corp

Withdrawn

Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease

Fabry Disease

Canada
Resverlogix Corp

Completed

Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease (ASSERT)

Coronary Artery Disease | Atherosclerosis

United States
Resverlogix Corp

Completed

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

Cardiovascular Disease | Atherosclerosis | Dyslipidemia | Acute Coronary Syndrome

United States
Resverlogix Corp
Nucleus Network Ltd; Baker Heart and Diabetes Institute

Completed

The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes

Diabetes

Australia
Resverlogix Corp

Not yet recruiting

A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis

Kidney Failure, Chronic
Aravax Pty Ltd

Recruiting

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Immune System Diseases | Peanut Hypersensitivity | Peanut Allergy | Peanut-Induced Anaphylaxis

United States, Australia
Novavax

Active, not recruiting

Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines (COVID-19)

COVID-19

United States
Vertex Pharmaceuticals Incorporated

Completed

Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects

Healthy

United States
Naurex, Inc, an affiliate of Allergan plc

Completed

Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers (NRX-1074)

Major Depressive Disorder

United States
Vertex Pharmaceuticals Incorporated

Completed

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Rheumatoid Arthritis

United States, Denmark, Estonia, Lithuania, Netherlands, South Africa
Vertex Pharmaceuticals Incorporated

Recruiting

Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)

Painful Lumbosacral Radiculopathy

United States
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Poland, Belgium, Romania, Serbia, United States, Puerto Rico, Germany, Hungary, Russian Federation, Croatia
Vertex Pharmaceuticals Incorporated

Completed

A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548

Pain

United States
Novavax

Completed

Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines (COVID-19)

COVID-19 | SARS CoV 2 Infection

Australia
Aptinyx
Worldwide Clinical Trials

Completed

Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)

Diabetic Peripheral Neuropathic Pain

United States
Vertex Pharmaceuticals Incorporated

Not yet recruiting

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

Pain
Vertex Pharmaceuticals Incorporated

Completed

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Rheumatoid Arthritis

United States, Argentina, Bulgaria, Czech Republic, Estonia, Germany, Hungary, Mexico, Poland, Romania, Russian Federation, Serbia, Slovakia, Ukraine
Medical University of Vienna

Not yet recruiting

Concomitant Administration of the Novavax Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years (NVX_PCV20)

COVID-19 | Pneumococcal Infections
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Estonia, Lithuania, South Africa
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants

Acute Pain

United Kingdom
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors

Cancer | Advanced Solid Tumors

United States
Novavax

Completed

Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

COVID-19 | SARS-CoV-2 Infection

United States
Reata, a wholly owned subsidiary of Biogen

Completed

A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

United States
Chong Kun Dang Pharmaceutical

Completed

Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects

Healthy Subjects

United Kingdom
NVP Healthcare

Completed

Pharmacokinetic Interaction and Safety Between NVP-1203-R1 and NVP-1203-R2 (Navipharm)

Healthy

Korea, Republic of
NVP Healthcare

Completed

Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2

Healthy

Korea, Republic of
NVP Healthcare

Withdrawn

Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2

Healthy
NVP Healthcare

Recruiting

To Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients

Cardiovascular Diseases

Korea, Republic of
NVP Healthcare

Completed

Efficacy and Safety of NVP-1203 and NVP-1203-R in Patients With Acute Low Back Pain

Acute Low Back Pain

Korea, Republic of
NVP Healthcare

Completed

Efficacy and Safety of NVP-1203 in Patients With Acute Low Back Pain

Acute Low Back Pain

Korea, Republic of
NVP Healthcare

Completed

NVP-1805 Compared to Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Adult Volunteers (BE)

Healthy Volunteers

Korea, Republic of
NVP Healthcare

Completed

Compare the Pharmacokinetics of NVP-1805 and Coadministration of NVP-1805-R1 With NVP-1805-R2 (NVP-1805)

Healthy

Korea, Republic of
GlaxoSmithKline

Completed

Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes

Asthma

United Kingdom
NVP Healthcare

Completed

Pharmacokinetic Characteristics and Safety After Administration of NVP-2002

Healthy

Korea, Republic of
NVP Healthcare

Completed

NVP-1805 Compared to Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Adult Volunteers (BE)

Healthy Volunteers

Korea, Republic of
NVP Healthcare

Completed

To Evaluate the Safety and the Pharmacokinetics of NVP-2203

Healthy Volunteers

Korea, Republic of
University of California, Los Angeles

Completed

Clinical Evaluation of Morcher Artificial Iris Diaphragms

Aniridia | Iris; Deformity

United States
NVP Healthcare

Completed

Evaluation of Pharmacokinetic and Safety of NVP-1705 and NVP-1705-R in Healthy Subjects

Healthy Subjects

Korea, Republic of
NVP Healthcare

Completed

Evaluation of Pharmacokinetic and Safety of NVP-2102 and NVP-2102-R in Healthy Subjects

Healthy Subjects

Korea, Republic of
Evaxion Biotech A/S
Novotech (Australia) Pty Limited

Terminated

Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

Melanoma Stage IV | Melanoma Stage III

Australia
NFlection Therapeutics, Inc.

Completed

NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

Neurofibromatosis 1 | Cutaneous Neurofibroma

United States
Vyluma, Inc.
Syneos Health

Active, not recruiting

CHAMP: Study of NVK-002 in Children With Myopia

Myopia

United States, Hungary, Ireland, Netherlands, Spain, United Kingdom
NVP Healthcare

Completed

A Study to Evaluate the Safety and Pharmacokinetics of NVP-1402

Healthy

Korea, Republic of
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy (CLMF237A1303)

Diabetes Mellitus, Type 2

Japan

3

Subscribe